Changes in serum potassium in people with type 2 diabetes taking sodium‐glucose co‐transporter‐2 inhibitors
No clinically significant increase or decrease in potassium levels was observed upon initiation of SGLT2 inhibitor therapy in patients with T2D. This was consistent across background medication use and patient-specific factors. Baseline potassium should not be a factor in initiating SGLT2 inhibitor therapy, if clinically indicated, in patients with T2D.
Authors
- Christie Schumacher (ORCID: https://orcid.org/0000-0002-6501-1590)
- Elizabeth Van Dril (ORCID: https://orcid.org/0000-0002-6138-1113)
- Charlotte Bolch (ORCID: https://orcid.org/0000-0002-9797-6557)
- Kellye Eagan
Institutions
- Midwestern University (US)
- University of Illinois Chicago (US)
- Advocate Health Care (US)
Publication Details
- Journal
- Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
- Published
- 2025-02-23
- DOI
- https://doi.org/10.1002/phar.70006
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00